Bioptimus, a French startup, has collaborated with Proscia to accelerate AI innovation in scientific research and drug development for improved patient care. The partnership makes Bioptimus’ H-optimus-0 foundation model available on Proscia’s Concentriq platform, enabling researchers and data scientists to develop AI models at unprecedented speed and scale. H-optimus-0 is the largest open-source AI foundation model tailored specifically for pathology, with 1.1 billion parameters, delivering state-of-the-art performance in critical tasks such as detecting cancerous cells and identifying genetic abnormalities in tumors.
David Cahané, Co-Founder and General Manager at Bioptimus, said that H-optimus-0 has set new benchmarks in AI performance and will empower the scientific community to achieve breakthroughs in precision medicine and therapeutic research. David West, CEO at Proscia, added that the integration of H-optimus-0 into Concentriq Embeddings will help users rapidly build high-performing algorithms at scale, unlocking the promise of AI-driven therapeutic research and development.
Accelerating AI Innovation in Scientific Research and Drug Development
The collaboration between Bioptimus and Proscia marks a significant milestone in the development of artificial intelligence (AI) in scientific research and drug development. The integration of Bioptimus’ H-optimus-0 foundation model with Proscia’s Concentriq Embeddings enables researchers and data scientists to accelerate AI innovation at an unprecedented scale.
H-optimus-0, a cutting-edge AI foundation model tailored specifically for pathology, boasts 1.1 billion parameters, making it the largest open-source AI foundation model in its class. This model has demonstrated state-of-the-art performance in critical tasks, such as detecting cancerous cells and identifying genetic abnormalities in tumors. By leveraging H-optimus-0, researchers can now develop AI-driven models that enhance the precision and efficiency of pathology diagnostics.
The integration with Concentriq Embeddings allows users to seamlessly apply their organization’s large proprietary datasets to H-optimus-0 and execute it in routine R&D workflows. This enables data scientists and researchers to build high-performing algorithms at scale, unlocking the promise of AI-driven therapeutic research and development.
The Power of Real-World Data in Enhancing Foundation Models
Proscia’s real-world data (RWD) has played a pivotal role in the success of foundation models like H-optimus-0. High-quality, diverse, and clinically relevant datasets have enabled the creation of scalable models capable of powering large-scale AI development across multiple therapeutic areas. These models are transforming pathology AI development and enabling innovations that can ultimately bring therapies to patients faster.
The use of RWD has allowed for the creation of foundation models that can generalize effectively across different scenarios. This is exemplified by H-optimus-0, which was trained on a vast dataset of over 500,000 pathology slides, exposing it to a diverse array of cases. The model’s ability to generalize effectively has enabled it to consistently meet or outperform existing models in the field.
Unlocking the Full Value of Foundation Models in Pathology AI
The collaboration between Bioptimus and Proscia highlights the importance of foundation models like H-optimus-0 in transforming pathology AI development. To explore this further, Bioptimus will join Proscia’s exclusive webinar, providing insights into practical strategies for leveraging these advanced models to accelerate AI innovation in pathology.
Key topics include the pivotal role of computational pathology in driving breakthroughs in precision medicine and therapeutic R&D, as well as how foundation models like H-optimus-0 are transforming AI development in pathology. This webinar aims to provide a comprehensive understanding of the potential of foundation models in unlocking the full value of AI-driven innovation in pathology.
The Future of Pathology AI Development
The collaboration between Bioptimus and Proscia marks a significant step forward in the development of AI in scientific research and drug development. As the field continues to evolve, it is clear that foundation models like H-optimus-0 will play an increasingly important role in driving innovation.
With the ability to accelerate AI innovation at scale, researchers and data scientists can now develop high-performing algorithms that unlock the promise of AI-driven therapeutic research and development. This has significant implications for the future of pathology AI development, enabling the creation of novel therapies and diagnostics that can drive the fight against humanity’s most challenging diseases.
About Bioptimus and Proscia
Bioptimus is a company building the reference AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. Leveraging a team of world-class experts, employing state-of-the-art AI technologies, and accessing unique proprietary data at scale, Bioptimus aims to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data fuel the development and use of novel therapies and diagnostics to drive the fight against humanity’s most challenging diseases, like cancer.
External Link: Click Here For More
